These results suggest that genetic alterations of m6A regulatory genes in cooperation with TP53 contribute to the pathogenesis and maintenance of AML, and provide a rationale for therapeutic targeting of METTL3 in myeloid leukemia. This evidence concerns the gene TP53 and acute myeloid leukemia.